Skip to main content
. 2002 Mar;13(3):755–766. doi: 10.1091/mbc.01-09-0437

Figure 5.

Figure 5

Mad2B and Bub3 do not have synergistic effect with BubR1 in inhibiting Cdc20. (A) Dose response of Mad2B in inhibition of Cdc20. Decreasing amounts of recombinant Mad2B were incubated with constant amounts of Cdc20 and iAPC. The ability of treated APC to ubiquitinate the radioactive N-terminal fragment of cyclin B was assayed. (B) Various amounts of recombinant Mad2B were incubated with constant amounts of BubR1, Cdc20, and iAPC. The ability of treated APC to ubiquitinate the radioactive N-terminal fragment of cyclin B was assayed. (C) Interphase APC (lane 1) was incubated with recombinant Cdc20 (lane 2), Cdc20 plus BubR1 (lane 3), Cdc20 plus Bub3 (lane 4), or Cdc20 plus BubR1 and Bub3 (lane 5), and the ubiquitin ligase activity of treated APC was assayed.